GLAUKOS CORP

Company Overview

Glaukos Corp (GKOS) is a California‑based ophthalmic pharmaceutical and medical‑technology company focused on “dropless” therapies and micro‑invasive surgical devices for glaucoma, corneal disorders (keratoconus) and retinal disease. Its principal commercial portfolio includes the iStent family (MIGS), the recently launched iDose TR intracameral travoprost implant, and the iLink corneal cross‑linking system; in 2024 ~79% of net sales were from glaucoma products and ~21% from corneal health. The company sells predominantly via a U.S. direct sales force to surgeons, ASCs and hospitals (about 70% U.S. sales; ~80% of iStent procedures occur in ASCs), runs heavy clinical and regulatory programs, and is sensitive to reimbursement, FDA/PMA and coding decisions.

Executive Compensation Practices

Given Glaukos’s growth-by-launch model, executive pay is likely weighted toward equity and performance‑based awards tied to commercial ramps (iDose TR and iStent infinite volumes), revenue growth and procedural adoption metrics rather than cash bonuses alone—management disclosed higher compensation and performance‑based stock awards as a driver of SG&A. Long‑term incentives are also plausibly tied to regulatory and clinical milestones (PMA/IDE, PDUFA dates such as Epioxa Oct‑20‑2025 and iDose supplemental filings), IP and successful reimbursement coding, since these events materially affect valuation. Cash conservation needs (ongoing operating losses, net loss $146.4M in 2024, and active pipeline spend) plus periodic financing actions (convertible note exchange converting ~4.25M shares) make equity grants and milestone payouts a practical lever for retention and alignment.

Insider Trading Considerations

Insider trading patterns at Glaukos should be evaluated in light of frequent material regulatory and reimbursement catalysts (FDA approvals, PMA/IDE outcomes, MAC/LCD coverage and CMS coding) and financing/dilution events (convertible note conversions, capped‑call unwind). Expect insiders to rely on Rule 10b5‑1 plans and observe blackout windows around clinical readouts, PDUFA/PMA decisions and major reimbursement announcements; trades outside those windows—especially sales following equity conversions or ahead of adverse coverage news (e.g., recent MAC LCD impacts)—warrant scrutiny. Also monitor Section 16 filings for option exercises and subsequent sales (common when compensation is equity‑heavy), and watch insider buys as stronger positive signals given the company’s development risk and cash burn profile.